Disease Diagnosis TRIZ Cases

A Flow Cytometric Body Scan analyzes circulating tissue macrophages to evaluate physiological processes and detect early diseases.

Gas-phase ion mobility analysis replaces indirect chemical calculations with direct particle sizing to resolve accuracy and throughput trade-offs.

Urine BNP measurement resolves diagnostic reliability issues by replacing invasive blood sampling with non-invasive urine analysis for general practitioners.

Principal component analysis of metabolite profiles detects pre-symptomatic Age-Related Macular Degeneration before visual symptoms appear.

Oral and intravenous stable isotopologues enable precise nutrient absorption measurement via plasma ratio analysis.

Exogenous stress induction identifies differential protein expression to resolve predictive accuracy versus technical complexity in radiotherapy planning.

A protein complex comprising transthyretin and prostaglandin-H2 D-isomerase serves as a biomarker for quantifying neurodegenerative disorders in patient fluid samples.

Polypeptide marker antigens bind specifically to tumor autoantibodies in serum samples to enable precise biomarker identification.

Analyzing proADM, PCT, and proET-1 concentrations enables early detection of adverse events before clinical symptoms appear.

Integrating three endosomal biomarkers resolves false-positive rates in PSA screening while distinguishing aggressive from slow-growing cancers.

Antibody panels detect lung cancer epitopes in plasma, resolving the trade-off between detection sensitivity and specificity found in LDCT imaging.

Anti-THEX1 autoantibody detection resolves diagnostic delays from classical marker absence, achieving 94% specificity for accurate disease monitoring.

Kidney injury markers detect acute renal failure earlier than creatinine tests, resolving delayed diagnosis bottlenecks.

Measuring HE4 and Cyfra21-1 concentrations replaces costly imaging to detect relapse without radiation exposure while improving diagnostic accuracy.

A biomarker panel predicts therapeutic responses to anti-TNF therapy in Crohn's disease patients.

Vertically aligned carbon nanotubes increase surface area to resolve the trade-off between detection sensitivity and device complexity.

Protein expression profiling detects familial adenomatous polyposis before clinical symptoms appear, resolving unclear genetic test results.

A CHI3L1 biomarker assay measures protein levels in blood serum to identify nonalcoholic steatohepatitis risk and progression stages.

Adjusting sample dilution ratios resolves irrelevant positivity thresholds for immunocompromised patients, ensuring accurate diagnostic results.

A capillary substrate with fluorescent markers binds target biomolecules and emits proportional radiation, resolving complexity trade-offs in fertility testing.

Simultaneous expression of amyloid precursor and TonB proteins resolves the contradiction between high diagnostic accuracy and limited protein availability.

Measuring glyceraldehyde 3-phosphate dehydrogenase levels via ELISA resolves the trade-off between diagnostic accuracy and invasive, expensive procedures.

A diagnostic method using URG7 peptide fragment 75-99 detects anti-URG7 antibodies in serum samples via ELISA assays.

Specific ceramide and lysophospholipid markers predict cardiovascular events through concentration analysis in biological samples.

Segmenting targeting and therapeutic modules via an aptamer-agent conjugate inhibits CD117-positive AML growth while sparing normal cells.

Uncomplexed PF4 ELISA detects VITT antibodies to resolve sensitivity and specificity trade-offs in thrombotic condition diagnosis.

A home-based testing kit determines urine neutrophil activation marker levels to monitor inflammation status.

Incubation forms polypeptide aggregates detected by hydrophobic binder-labels to resolve low antigen sensitivity in biosamples.

A lectin-based assay detects fucosylated proteins in biological samples to identify liver pathology markers.

Calculating sFlt-1 to PlGF ratios identifies postpartum preeclampsia risk before severe complications arise.

Multiple reaction monitoring mass spectrometry with labeled peptides resolves immunoassay interference to accurately quantify histones in septic shock plasma.

Monoclonal antibodies target immunogenic insulin peptides, resolving the trade-off between mass spectrometry precision and system complexity.

Engineered biosensor cells detect seed tau protein at attomolar levels using reporter proteins and fluorescence resonance energy transfer.

A lateral flow assay detects intraocular fluid biomarkers using a blood filter and specific target recognition elements.

Biomarker detection identifies chronic kidney disease progression risk to enable personalized treatment strategies.

Combining hyaluronic acid and S100P in plasma samples resolves the trade-off between diagnostic accuracy and patient invasiveness compared to tissue biopsies.

Detecting ddit4 and ccl21 expression levels in blood samples enables non-invasive atrial fibrillation screening.

Urine assays detect the MMP9:TIMP2 complex to identify acute kidney injury risk before serum creatinine levels rise, enabling earlier clinical intervention.

Automated Quantitative Image Analysis determines the nuclear to cytoplasmic ratio of MRE11 protein expression in tissue samples.

A biomimetic coating immobilizes capture molecules on a dissolvable hydrogel matrix to isolate rare cells from blood samples.

A Chromogranin A immunoassay uses antibodies targeting conformational epitopes to form a ternary complex for analyte detection.

Follistatin-related protein 3 identifies acute kidney injury earlier than serum creatinine, resolving timing and precision trade-offs.

Anti-podocin antibody detection of urinary podocytes classifies preeclampsia, reducing unnecessary treatment and maternal morbidity.

Blood-based autoantibody biomarker assay detects early-stage Parkinson's disease through immunocomplex formation.

A biochemical marker panel assesses cardiovascular risk using specific proteins.

Measuring IGFBP7 prior to procedures enables early AKI detection, overcoming the delayed and nonspecific nature of serum creatinine markers.

A biomarker system identifies cancer cells with low antiviral gene expression to enable targeted oncolytic virus administration.

Detect circulating glucagon-like peptide 1 and 2 levels in biological samples for rapid intestinal ischemia identification.

A lateral flow assay detects CD30 and cytokines in seroma fluid for rapid point-of-care diagnosis.